CytoVac is talking to potential partners
Denmark-based biotech CytoVac is in talks with several foreign companies concerning a partnership. The company’s candidate drug to treat brain cancer is ready to be tested in patients in clinical phase II studies.
by Henrik Tüchsen
Denmark-based biotech CytoVac, which has just begun recruiting patients for a phase II study in brain cancer, is talking to a number of potential collaboration partners. The company will need to bring a partner on board this year, or raise additional funds from current investors for completion of the phase II project.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
